This proof-of-concept study demonstrates that TCR-based therapies can be improved with engineered T cells expressing a costimulatory chimeric antigen receptor (CoCAR). CoCAR+ T cells are able to kill TCR targets,… Click to show full abstract
This proof-of-concept study demonstrates that TCR-based therapies can be improved with engineered T cells expressing a costimulatory chimeric antigen receptor (CoCAR). CoCAR+ T cells are able to kill TCR targets, while sparing normal cells expressing the CoCAR antigen.
Keywords:
improves tcr;
costimulatory car;
car improves;
costimulatory;
tcr based;
cancer
Journal Title: Cancer Immunology Research
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer Immunology Research
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!